{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-030563","form_type":"8-K","ticker":"HROW","cik":"0001360214","company_name":"HARROW, INC.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.780218+00:00","generated_at":"2026-05-31T11:39:21.712930+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Harrow Q2 2024 record revenue $48.9M (+46% YoY); adj EBITDA $8.8M; guides FY rev >$180M","bullets":["Record Q2 revenue $48.9M, up 46% YoY and 42% sequentially; GAAP net loss $(6.5)M.","Adjusted EBITDA $8.8M; core gross margin 79% (up from 78%).","IHEEZO unit demand up 98% QoQ; VEVYE prescriptions up 212% QoQ; new IHEEZO supply agreements.","FY2024 revenue guidance >$180M (excluding TRIESENCE); expects back-half outperformance.","TRIESENCE PPQ Batch 2 passes initial tests; third batch scheduled; potential 2024 relaunch."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-030563","json":"https://secwatch.observer/filing/0001493152-24-030563.json","markdown":"https://secwatch.observer/filing/0001493152-24-030563.md","text":"https://secwatch.observer/filing/0001493152-24-030563.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1360214/000149315224030563/0001493152-24-030563-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1360214/000149315224030563/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:39:21.712930+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}